Literature DB >> 22287936

Pharmacogenetics of antipsychotic treatment response and side effects.

B Mackenzie1, Rp Souza, O Likhodi, Ak Tiwari, Cc Zai, J Sturgess, Dj Müller.   

Abstract

Antipsychotic drugs are particularly interesting in pharmacogenetic studies as they are associated with a large interindividual variability in terms of response and side effects and, therefore, frequently need to be discontinued, requiring switches to other antipsychotics. Any information that allows the prediction of outcome to a given antipsychotic in a particular patient will, therefore, be of great help for the clinician to minimize time and find the right drug for the right patient, thus optimizing response and minimizing side effects. This will also have a substantial impact on compliance and doctor-patient relationships. Moreover, antipsychotic drug treatments are often required for life-long treatment and are also frequently prescribed to the more 'vulnerable' populations: children, adolescents and the elderly. This article focuses on some important studies performed with candidate gene variants associated with antipsychotic response. In addition, important findings in pharmacogenetic studies of antipsychotic-induced side effects will be briefly summarized, such as antipsychotic treatment induced tardive dyskinesia and weight gain.

Entities:  

Year:  2010        PMID: 22287936      PMCID: PMC3266305          DOI: 10.2217/thy.10.3

Source DB:  PubMed          Journal:  Therapy        ISSN: 1475-0708


  66 in total

1.  Investigation of promoter variants of the histamine 1 and 2 receptors in schizophrenia and clozapine response.

Authors:  D Mancama; M J Arranz; J Munro; S Osborne; A Makoff; D Collier; R Kerwin
Journal:  Neurosci Lett       Date:  2002-11-29       Impact factor: 3.046

2.  Association study of apolipoprotein E epsilon4 with clinical phenotype and clozapine response in schizophrenia.

Authors:  C J Hong; Y W Yu; C H Lin; H L Song; H C Lai; K H Yang; S J Tsai
Journal:  Neuropsychobiology       Date:  2000       Impact factor: 2.328

3.  Association study of 12 polymorphisms spanning the dopamine D(2) receptor gene and clozapine treatment response in two treatment refractory/intolerant populations.

Authors:  Rudi Hwang; Takahiro Shinkai; Vincenzo De Luca; Daniel J Müller; Xingqun Ni; Fabio Macciardi; Steven Potkin; Jeffrey A Lieberman; Herbert Y Meltzer; James L Kennedy
Journal:  Psychopharmacology (Berl)       Date:  2005-10-15       Impact factor: 4.530

4.  Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine.

Authors:  J Kane; G Honigfeld; J Singer; H Meltzer
Journal:  Arch Gen Psychiatry       Date:  1988-09

Review 5.  Tardive dyskinesia: prevalence and risk factors, 1959 to 1979.

Authors:  J M Kane; J M Smith
Journal:  Arch Gen Psychiatry       Date:  1982-04

6.  MCP-1 gene (SCYA2) and schizophrenia: a case-control association study.

Authors:  Emanuela Mundo; A Carlo Altamura; Serena Vismara; Roberta Zanardini; Stefano Bignotti; Roberto Randazzo; Claudio Montresor; Massimo Gennarelli
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2005-01-05       Impact factor: 3.568

7.  Allelic association between a Ser-9-Gly polymorphism in the dopamine D3 receptor gene and schizophrenia.

Authors:  S Shaikh; D A Collier; P C Sham; D Ball; K Aitchison; H Vallada; I Smith; M Gill; R W Kerwin
Journal:  Hum Genet       Date:  1996-06       Impact factor: 4.132

8.  Increased incidence of CYP2D6 gene duplication in patients with persistent mood disorders: ultrarapid metabolism of antidepressants as a cause of nonresponse. A pilot study.

Authors:  Chiaki Kawanishi; Stefan Lundgren; Hans Agren; Leif Bertilsson
Journal:  Eur J Clin Pharmacol       Date:  2003-12-02       Impact factor: 2.953

9.  CYP2D6 genotype: impact on adverse effects and nonresponse during treatment with antidepressants-a pilot study.

Authors:  Thomas Rau; Gerlinde Wohlleben; Henrike Wuttke; Norbert Thuerauf; Jens Lunkenheimer; Mario Lanczik; Thomas Eschenhagen
Journal:  Clin Pharmacol Ther       Date:  2004-05       Impact factor: 6.875

10.  The --1019 C/G polymorphism of the 5-HT(1)A receptor gene is associated with negative symptom response to risperidone treatment in schizophrenia patients.

Authors:  L Wang; C Fang; A Zhang; J Du; L Yu; J Ma; G Feng; Q Xing; L He
Journal:  J Psychopharmacol       Date:  2008-02-28       Impact factor: 4.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.